CYDY
CytoDyn Inc.
Set alert
0.22 USD -0.01 -4.35%
0.2171 Day range 0.23
0.18 52-week range 0.40
- YTD
- -21.43%
- 1 year
- -8.33%
- Open
- 0.225
- Prev close
- 0.23
- Mkt cap
- 323.29M
- Vol
- 386.29K
- Avg vol
- 1.83M
- EPS
- -0.03
- P/E
- 0.00
More statistics
- Low
- 0.2171
- High
- 0.23
- Earnings
- Jan 21, 2025
Next earnings
Jan 21, 2025
Expected Jan 21, 2025. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 21, 2025 | Nov 1, 2024 | 0.00 | — | — | — |
| Oct 15, 2024 | Aug 1, 2024 | 0.00 | 0.02 | — | — |
| Aug 15, 2024 | May 1, 2024 | 0.00 | -0.02 | — | — |
| Apr 15, 2024 | Feb 1, 2024 | 0.00 | -0.01 | — | — |
| Jan 16, 2024 | Nov 1, 2023 | 0.00 | -0.01 | — | — |
| Oct 23, 2023 | Aug 1, 2023 | 0.00 | -0.01 | — | — |
News
- CytoDyn (OTCMKTS:CYDY) Shares Break Below Two Hundred Day Moving Average – Here’s What Happened
- CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026
- CytoDyn Inc. (CYDY) Discusses Latest Scientific, Clinical, Operational, and Financial Progress and Upcoming Priorities Transcript
- CytoDyn Highlights Early CLOVER Data, Names Robert Hoffman CEO
- CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer
- CytoDyn to Host Investor Webcast
- CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026
- CytoDyn Highlights CLOVER Progress, Early ctDNA Declines in Colorectal Cancer
- CytoDyn (OTCMKTS:CYDY) Stock Price Crosses Below Fifty Day Moving Average – Here’s Why
- CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th
Your note
Sign in to keep a note on CYDY — it syncs with the Stock Master app.